This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P &lt;0.0001). By dividing patients by STS<a href="https://solaci.org/en/2015/06/24/partner-cohort-b-5-year-results-of-a-balloon-expandable-valve-on-inoperable-patients/" title="Read more" >...</a>

Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement.&nbsp; The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,<a href="https://solaci.org/en/2015/06/24/us-corevalve-cost-effectiveness-of-transcatheter-replacement-versus-surgical-replacement-in-high-risk-patients/" title="Read more" >...</a>

This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery.&nbsp; The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for<a href="https://solaci.org/en/2015/06/24/corevalve-us-pivotal-trial-2-year-results-of-the-self-expanding-valve-on-inoperable-patients/" title="Read more" >...</a>

Aortic regurgitation after valve implantation has been shown to be a long -term mortality predictor. The aim of this study was to test the new Direct Flow Medical system, which is more flexible prosthesis with a lower profile that could result in minor aortic regurgitation and less need for post expansion. This multicenter study included<a href="https://solaci.org/en/2015/06/24/salus-new-percutaneous-valve-with-promising-results-regarding-aortic-regurgitation-post-implant/" title="Read more" >...</a>

So far, there had been no published randomized studies comparing balloon-expandable Edwards&rsquo;s prosthesis and self-expandingCoreValve. The aim of this study was to compare the results between the two thin aortic prosthesis in high-risk surgical patients with severe symptomatic aortic stenosis undergoing valve replacement by percutaneous transfemoral access. This was a multicenter work (five centers in<a href="https://solaci.org/en/2015/06/24/choice-trial-same-mortality-less-aortic-regurgitation-and-need-for-a-second-prosthetic-for-edwards-sapien-xt-valve-versus-medtronic-corevalve/" title="Read more" >...</a>

Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant in 2011 were included. As recommended in the European Cardiovascular Guidelines, this national registry suggests that percutaneous implant represents the dominant treatment of this disease, especially in high-risk patients. In high-risk<a href="https://solaci.org/en/2015/06/24/gary-german-aortic-valve-registry/" title="Read more" >...</a>

The objective was to evaluate the safety and efficacy of the Lotus Valve System to treat patients with severe aortic stenosis and high surgical risk. The study included 60 patients who received the device and were followed during 30 days. Mortality from all causes was 1.7% and the incidence of stroke was 8.6%, with half<a href="https://solaci.org/en/2015/06/24/reprise-ii-results-obtained-with-the-new-valve-according-to-varc-criteria/" title="Read more" >...</a>

Percutaneous aortic valve implantation ( TAVI ) recently demonstrated its superiority over medical treatment in patients with severe aortic stenosis and high surgical risk. Furthermore patients receiving TAVI showed a survival surgery equivalent to one year. This study included 471 patients with symptomatic severe aortic stenosis discarded of surgery due &nbsp;a very high risk. The<a href="https://solaci.org/en/2015/06/24/corevalve-extreme-risk-promising-results-with-corevalve-in-very-high-risk-patients/" title="Read more" >...</a>